Global Antifibrinolytic Market, By Drugs (Aminocaproic Acid, Tranexamic Acid, Others), Indication (Gynecology, Gastrointestinal Bleeding, Hereditary Angioedema, Hemorrhage, Surgeries, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Antifibrinolytic Market Analysis and Size
The global antifibrinolytic market is expected to witness significant growth during the forecast period. Bleeding disorders have been increasing and as a result, the antifibrinolytic market is growing. These antifibrinolytic can be used to prevent severe bleeding in patients suffering from life threatening conditions such as hemophilia, serious menstrual bleeding, or many types of vascular tumors. Several government initiatives are being taken in this regard that aided in the awareness of the diseases. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global antifibrinolytic market in the forecast period 2022-2029. The expected CAGR of global antifibrinolytic market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 15 billion in 2021, and it would grow upto USD 22.16 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Antifibrinolytic are a type of therapeutics that helps in blood clotting by restricting the process called fibrinolysis. Many antifibrinolytics such as tranexamic acid exert their action by reversibly binding to the lysine receptor sites located into plasminogen, thus preventing fibrin degradation. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Antifibrinolytic Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Drugs (Aminocaproic Acid, Tranexamic Acid, Others), Indication (Gynecology, Gastrointestinal Bleeding, Hereditary Angioedema, Hemorrhage, Surgeries, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceuticals Industries Ltd. (India), Amneal Pharmaceuticals LLC. (U.K.), Alvogen (U.S.), Akorn, Incorporated (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan) |
|
Market Opportunities |
|
Global Antifibrinolytic Market Dynamics
Drivers
- Growing Demand of Trauma Centers Segment
The trauma centers segment is expected to grow at the fastest rate due to the substantial increase in road accidents all over the globe. Road traffic injury death rates are the most in the African region. Even in highly developed countries, people from lower socioeconomic backgrounds may be involved in road traffic crashes. Thus, this boosts the market growth.
- Huge Demand For Gynaecologic Syndromes
The rising adoption of these drugs prevents menorrhagia, which means heavy menstrual flow. Additionally, these drugs are manufactured to decrease bleeding by inhibiting endometrial clot-dissolving enzymes in the uterine lining. In this regards, Tranexamic acid (TXA) is the most extensively used drug for controlling menorrhagia.
Opportunities
- Increasing Demand for Retail Pharmacies
The rise in the number of antifibrinolytic therapeutics being delivered through these retail pharmacies and the surge in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Impending Drug Approvals
There are many drugs or injections that await for the approval of the drugs. Receiving approval for the drug from regulatory authorities is a very tedious and challenging task as regulatory authorities such as the U.S. FDA execute substantial and burdensome requirements upon companies involved in the clinical development, marketing, manufacturing, and distribution of drugs
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global antifibrinolytic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global antifibrinolytic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Antifibrinolytic Market Scope
The global antifibrinolytic market is segmented on the basis of drug, indications, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug
- Aminocaproic Acid
- Tranexamic Acid
- Others
Indications
- Gynecology
- Gastrointestinal Bleeding
- Hereditary Angioedema
- Hemorrhage
- Surgeries
- Others
Route of Administration
- Oral
- Injectable
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Antifibrinolytic Market Regional Analysis/Insights
The global antifibrinolytic market is analysed and market size insights and trends are provided by drug, indications, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global antifibrinolytic market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high adoption of antifibrinolytic drugs, presence of refined healthcare infrastructure and increased patient awareness level as well as high prevalence of bleeding disorders.
Asia-Pacific dominates the market due to the presence of key generic players in this region and rise in cases of surgeries.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Antifibrinolytic Market Share Analysis
The global antifibrinolytic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global antifibrinolytic market.
Key players operating in the global antifibrinolytic market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceuticals Industries Ltd. (India)
- Amneal Pharmaceuticals LLC. (U.K.)
- Alvogen (U.S)
- Akorn, Incorporated (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
SKU-
